CWAF
ALXN

Core Wealth Advisors (Florida)’s Alexion Pharmaceuticals ALXN Stock Holding History

Core Wealth Advisors (Florida)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,238
Closed -$1.33M – 211
2021
Q2 		$1.33M Buy
+7,238
New +$1.24M 0.89% 12

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Core Wealth Advisors (Florida)'s ALXN Position: Q3 2021 in Review

Core Wealth Advisors (Florida) sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 7,238 shares — an estimated $1.33M sold.

Core Wealth Advisors (Florida) first reported a position in ALXN in Q2 2021 and held it in 1 quarter. The position peaked at $1.33M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Core Wealth Advisors (Florida) reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Core Wealth Advisors (Florida) sold 7,238 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.33M.
  • Core Wealth Advisors (Florida) first reported a position in Alexion Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Core Wealth Advisors (Florida)'s Alexion Pharmaceuticals position peaked at $1.33M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Core Wealth Advisors (Florida)'s 13F filing for Q3 2021, filed 9 Nov 2021.